Retatrutide is a new treatment in the fight against obesity. This novel drug, belonging to a dual GLP-1 and GIP receptor agonist, demonstrates promising results in clinical trials. By stimulating these receptors, Retatrutide controls cravings, {promotesinsulin secretion, and ultimately leads to significant reduction in body mass. While research is